

Amended or Supplemental Information Disclosure Statement regarding U.S. Application
No. 10/037718, Title of the Invention: Two-Dimensional Linkage Study Methods and
Related Inventions. March 04, 2004 Atty's Docket No. 2DLSM&R12/01

1 of 3



In the United States Patent and Trademark Office

In re application of:

Inventors: MCGINNIS, Ralph Evan and
MCGINNIS, Robert Owen

Title of the Invention: "Two-Dimensional Linkage Study Methods and Related
Inventions."

U.S. Application No. 10/037718

Date of filing: 04 January 2002

Examiner Kenneth R. Horlick, Art Unit 1637

Patent application 10/037718 is a continuation-in-part of U.S. Patent Application
09/947,768 (filed 5 SEPT 2001), now abandoned. And 09/947,768 claims priority from
US Provisional 60/230570 (filed 9/5/2000). Patent Application 09/947,768 is a
continuation-in-part of U.S. Patent Application 09/623,068 (filed 26 AUG 2000). The
present patent application is also a continuation-in-part of Patent Application 09/623,068
(filed 26 AUG 2000). Application 09/623,068 claims priority from PCT/US99/04376 filed
(2/26/99). PCT/US99/04376 claims priority from US Provisional applications: 60/076182
filed 27Feb1998, 60/086947 filed 27May1998, 60/076102 filed 26 Feb 1998 and
60107673 filed 7 Nov 1998.

Amended Information Disclosure Statement

c/o Honorable Commissioner of Patents
Alexandria, Va. 22313

Sir:

This submission is a supplemental or amended IDS. Attached hereto is an amended
version Form PTO/SB/08B (3 sheets) listing documents believed relevant to the subject
application. The form has been amended by eliminating the words "OTHER PRIOR
ART" from the listing heading. This was done to signify that no reference in this
amended IDS or previously filed original IDS (April 04, 2002) is admitted by the
applicants to be prior art with respect to the invention by the reference's listing in the
IDS. Form PTO/SB/08A (1 sheet) is also included. This sheet is unchanged from the
original IDS.

In addition, four new references (labeled X, Y, Z, and AA) have been added at the end of the listing on sheet 3. It is respectfully requested that these new documents (labeled X, Y, Z, and AA) be considered by the examiner and an initialed copy of sheets 1-4, with initials next to the references (including those labeled X, Y, Z, and AA) be returned to the undersigned. Each of these references (labeled X, Y, Z, and AA) is a published abstract of a poster or a slide presentation. Reference X is an abstract of a poster session presented Oct 7 and 10, 1991; reference Y is an abstract of a poster session presented Oct. 7 and 8, 1993; reference Z is an abstract of a slide session presented Oct. 26, 1995; and reference AA is an abstract of a poster session presented Oct. 30, 1996. All of these abstracts were published before the actual presentations.

This disclosure statement should not be construed as a representation that a search has been made or that no other material information as defined in 37 C.F.R. 1.56 (a) or similar requirements exists.

It is believed that this disclosure complies with the requirements of 37 C.F.R. 1.56, 1.97, 1.98 and the M.P.E.P. 609 and similar requirements. If for some reason the examiner considers otherwise, it is respectfully requested that the undersigned be notified.

A copy of each document (labeled X, Y, Z, and AA) is enclosed. Some of the documents may have markings thereon. No significance is meant to be attached to the markings. These documents are not necessarily analogous art. Each of these documents (labeled X, Y, Z, and AA) is listed in the bibliography of the inventor's unpublished manuscript (submitted to the American Journal of Human Genetics, included with previous provisional priority documents and cited in the patent application) or the inventor's published paper that is incorporated by reference into the patent application (Annals of Human Genetics, 1998, 62: pp. 159 to 179; a copy of which was included with the original IDS).


A copy of each of documents A through W was previously enclosed with the original IDS or related applications. And the Examiner returned an initialed copy of the original IDS indicating that he had previously considered each of references A through W and each of patent documents 1 through 5 in the original IDS. A copy of patent document 5 was enclosed in the original IDS, a copy of patent documents 1 through 4 inclusive was not included with the original IDS as these references were essentially cumulative or were priority documents for the present application. Document 5 is not necessarily analogous art. These documents, documents A through AA inclusive, are not necessarily analogous art.

Document A is discussed in the background and specification of the patent application and is incorporated into the application by reference. Document B is discussed in the specification and incorporated by reference in the patent application. Documents C through I inclusive and documents O and P are discussed in the background of the patent application. Documents F, I, O, and P inclusive were listed by the examiner in the International Search Report for PCT/US99/04376. Document 5 was "made of record as a document of interest" by the U.S. examiner during the examination of US National Application 09/623068. The documents believed to be most relevant are A, D, E, F, M, Q, R, S, T, U and V.

Amended or Supplemental Information Disclosure Statement regarding U.S. Application
No. 10/037718, Title of the Invention: Two-Dimensional Linkage Study Methods and
Related Inventions. March 04, 2004 Atty's Docket No. 2DLSM&R12/01
3 of 3


Other Information: A copy of the inventor's unpublished manuscript (submitted to the
American Journal of Human Genetics, included with previous provisional priority
documents and cited in the patent application) is enclosed.

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "R McGinnis".

Robert O. McGinnis, Coinventor and U.S. Patent Agent 44, 232
Address for correspondence: 1575 West Kagy Blvd., Bozeman, Mt. 59715, phone 406-
522-9355

March 04, 2004



Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 4

Complete if Known

Application Number 10/037718

Filing Date 04 JAN 2002

First Named Inventor MCGINNIS, R.E.

Group Art Unit 1637

Examiner Name Hortick, K.

Attorney Docket Number 2DLSM&R12/01

OTHER ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	A	MCGINNIS, R.E., Annals of Human Genetics, Vol. 62, pp. 159-179, (1998).
	B	MCGINNIS, R.E., et. al., Genetic Epidemiology, Vol. 12, pp. 637-640, (1995).
	C	RISCH, N. and MERIKANGAS, K., Science, Vol. 273, 13 Sept. 1996, pp. 1516-1517.
	D	MULLER-MYHSOK, B. and ABEL, L., Science, Vol. 275, 28 Feb 1997, (Technical Comments), pp. 1328-1329.
	E	RISCH, N. and MERIKANGAS, K., Science, Vol. 275, 28 Feb 1997, (Technical Comments), p. 1330.
	F	KRUGLYAK, L., Nature Genetics, Vol. 17, Sept. 1997, pp. 21-24.
	G	REED, P.W., et. al., Nature Genetics, Vol. 7, July 1994, pp. 390-395.
	H	LEVINSON, D.F., et. al., Amer. J. Psychiatry, Vol. 155, no. 6, June 1998, pp. 741-750.
	I	KRUGLYAK, L., Amer. J. Human Genetics, Vol. 62, 1998, pp. 994-996.
	J	BENNETT, S.T., et. al., Nature Genetics, Vol. 9, March 1995, pp. 284-292.
	K	JULIER, C., et. al., Nature, Vol. 354, 14 Nov. 1991, pp. 155-159.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Application Number	101037718
Filing Date	04 JAN 2002
First Named Inventor	MCGINNIS, R.E.
Group Art Unit	1637
Examiner Name	Horlick, K.
Attorney Docket Number	2 PLSM & R 12/01

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	L	CHARTIER - HARLIN, M.C., et. al., Hum. Mol. Genet. vol. 3, No. 4, 1994, pp. 569-574.	
	M	TU, I-P. and WHITTEMORE, A.S., Amer. J. Hum. Genet., vol. 64, 1999, pp. 641-649.	
	N	ABEL, L. and MULLER-MYHSOK, B., Amer. J. Hum. Genet., vol. 63, 1998, pp. 664-667.	
	O	KRUGLYAK, L. et. al., Amer. J. Hum. Genet., vol. 57, 1995, pp. 439-454.	
	P	KRUGLYAK, L., et. al., Amer. J. Hum. Genet., vol. 58, 1996, pp. 1347-1363.	
	Q	MCGINNIS, R.E., Amer. J. Hum. Genet., vol. 67, 2000, pp. 1340-1347.	
	R	TERWILLIGER, J.D. and OTT, J., Hum. Hered., vol. 42, 1992, pp. 337-346.	
	S	CLERGET-DARPOUX, F., et. al., Genetic Epidemiology, vol. 12, (1995) pp. 583-588	
	T	SCHORK, N.J., et. al., Am. J. Hum. Genet., vol. 67, 2000, pp. 1208-1218.	
	U	COOKSON, W.O.C., Abstract, 3rd International Mtg. on SNP and Complex Genome Analysis, 8-11 Sept. 2000.	
	V	DARVASI, A. & MCGINNIS, R.E., Am. J. Hum. Genet. Suppl 63:A229, Poster Abstract, Oct. 27-31, 1998.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Required to respond to a collection of information unless it contains a valid OMB

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known Application Number 10/037718 Filing Date 04 JAN 2002 First Named Inventor MCGINNIS, R-E. Group Art Unit 1637 Examiner Name Horlick, K. Attorney Docket Number 2 DLSM&R12/01	
Sheet	3	of	4		

OTHER		ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	W	Affymetrix GeneChip HuSNP Mapping Assay, Tech Note No. 1 Part No. 700318 Rev 2, downloaded from Affymetrix Website Dec. 4, 2001	
	X	MCGINNIS, et. al. Linkage between the insulin gene (1q) region and susceptibility to IDDM. Am. J. Hum. Genet. Suppl. 49, A 476, (1991).	
	Y	MCGINNIS, R.E., Am. J. Hum. Genet. Suppl. 53 : A 831. (1993)	
	Z	MCGINNIS, R.E., Am. J. Hum. Genet. Suppl. 51 : A 12 (1995).	
	AA	MCGINNIS, R.E., Am. J. Hum. Genet. Suppl. 59 : A 184 (1996).	

Examiner Signature		Date Considered		
-----------------------	--	--------------------	--	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.